Sex-specific association of ACAT-1 rs1044925 SNP and serum lipid levels in the hypercholesterolemic subjects by Wu, Dong-Feng et al.
RESEARCH Open Access
Sex-specific association of ACAT-1 rs1044925 SNP












1 and Shang-Ling Pan
2
Abstract
Background: Acyl-CoA:cholesterol acyltransferase (ACAT) is a key enzyme in cellular cholesterol homeostasis and in
atherosclerosis. The cellular cholesterol efflux correlated with serum high-density lipoprotein cholesterol (HDL-C)
concentrations has shown to be impaired in hyperlipidemic mice. The present study was carried out to clarify the
association of ACAT-1 rs1044925 single nucleotide polymorphism (SNP) and serum lipid levels in the
hyperlipidemic subjects.
Methods: A total of 821 unrelated subjects (hyperlipidemia, 476; normolipidemia, 345) aged 15-80 were included
in the study. Genotyping of the ACAT-1 rs1044925 SNP was performed by polymerase chain reaction and
restriction fragment length polymorphism combined with gel electrophoresis, and then confirmed by direct
sequencing.
Results: There was no significant difference in the genotypic and allelic frequencies of ACAT-1 rs1044925 SNP
between the normolipidemic and hyperlipidemic subjects. The levels of total cholesterol (TC), HDL-C and
apolipoprotein (Apo) AI in hyperlipidemic subjects were different between the AA and AC/CC genotypes in male
but not in female (P < 0.05-0.01), the C allele carriers had higher serum TC, HDL-C and ApoAI levels than the C
allele noncarriers. The association of genotypes and serum HDL-C and ApoAI levels in hyperlipidemia was found
mainly in the male subjects with hypercholesterolemia but not in those with hypertriglyceridemia. There were no
significant differences in serum lipid levels between the AA and AC/CC genotypes in the normolipidemic subjects.
Conclusions: The present study shows that the C allele carriers of ACAT-1 rs1044925 SNP in male hyperlipidemic
subjects had higher serum TC, HDL-C and ApoAI levels than the C allele noncarriers. There is a sex (male)-specific
association of ACAT-1 rs1044925 SNP and serum HDL-C and ApoAI levels in the hypercholesterolemic subjects.
Introduction
Cholesterol is present in tissues and in plasma lipopro-
teins either as free cholesterol or cholesteryl esters. Cel-
lular cholesterol exists both as a free sterol and as
esterified cholesterol. Acyl-coenzyme A: cholesterol acyl-
transferase (ACAT) is an intracellular enzyme that bio-
synthesizes cholesteryl esters from long-chain fatty acyl-
CoA and cholesterol in various tissues [1], playing a
major role in cellular cholesterol homeostasis. ACAT
has been found to be present as two isoforms, ACAT-1
and ACAT-2, with different intracellular localizations,
membrane topology in mammalian species, and meta-
bolic function for each enzyme [2-4]. ACAT-1 is ubiqui-
tously expressed in various tissues and cells including
brain, adrenal glands, kidneys [5-7], and macrophages
[8] and is responsible for foam cell formation in macro-
phages, whereas ACAT-2 is expressed only in intestine
and liver [2,3,9] and is in charge of the cholesterol
absorption process in intestinal mucosal cells [10].
ACATs have been considered as a target to develop
novel therapeutic agents to control hypercholesterole-
mia, atherosclerosis, and Alzheimer’s disease [11]
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any medium, provided the original work is properly cited.because its potential role in cholesterol metabolism and
atherosclerosis. The inhibition of ACAT activity has
been associated with decreased plasma cholesterol levels
by suppressing cholesterol absorption and by diminish-
ing the assembly and secretion of apolipoprotein (Apo)
B-containing lipoproteins such as very low density lipo-
protein (VLDL). ACAT inhibition also prevents the con-
version of macrophages into foam cells in the arterial
walls, a critical event in the development of athero-
sclerosis [11,12]. However, whether ACAT inhibitors
will serve as effective antiatherosclerosis drugs is cur-
rently under debate. In two recent researches, non-slec-
tion ACAT inhibition is not an effective strategy for
limiting atherosclerosis, but may promote atherogenesis
[13,14]. ACAT-1 deficiency did not prevent the develop-
ment of atherosclerotic lesions either apoE-deficient or
LDLR-deficient mice [15,16]. Studies showed that
ACAT-1 deficiency is detrimental attribute to the cyto-
toxicity of accumulated free cholesterol caused by the
impaired cellular cholesterol efflux in hyperlipidemic
models [17,18]. Thus, a major effect of macrophage
ACAT-1 depletion may be a disrupted of ATP-binding
cassette transporter A1 (ABCA1)-mediated cholesterol
efflux in the lipid-loaden condition [18]. Moreover, the
extent of cholesterol efflux is highly correlated with
serum ApoAI and high-density lipoprotein cholesterol
(HDL-C) concentrations [19-21]. In a study of heterozy-
gous subjects for ABCA1 mutations, the levels of choles-
terol efflux account for 82% of the variation in HDL-C.
Each 8% change in ABCA1-mediated efflux is predicted
to be associated with a 0.1 mmol/L change in HDL-C
[20]. In addition, previous studies have found the
ACAT-1 gene polymorphisms affect serum HDL-C
levels in endogenous hypertriglyceridemia [22], as well
as hyperlipidemia [23]. Based on the above concept, we
hypothesize that the ACAT-1 rs1044925 SNP might
influence the cellular cholesterol efflux and regulate the
concentration of serum HDL-C and ApoAI in the
hyperlipidemic subjects. Therefore, the aim of the pre-
sent research was to determine whether the ACAT-1
rs1044925 SNP affect the concentration of serum lipid




A total of 476 Han Chinese subjects of hyperlipidemia
and 345 Han Chinese subjects of normolipidemia were
randomly selected from our previous stratified rando-
mized cluster samples [24,25]. The individuals with TC
> 5.17 mmol/L and/or triglyceride (TG) > 1.70 mmol/L
were defined as hyperlipidemica, hyperlipidemica was
divided into (type IIa) hypercholesterolemia (TC > 5.17
mmol/L and TG ≤ 1.70 mmol/L) and (types IIb, IV and
V) hypertriglyceridemia (TG > 1.70 mmol/L). The indi-
viduals with TC ≤ 5.17 mmol/L and TG ≤ 1.70 mmol/L
were defined as normolipidemic. All study subjects had
no evidence of any chronic illness, including hepatic,
renal, or thyroid. The participants with a history of
heart attack or myocardial infarction, stroke, congestive
heart failure, diabetes or fasting blood glucose ≥ 7.0
mmol/L determined by glucose meter have been
excluded. The participants were not taking medications
known to affect serum lipid levels. The present study
was approved by the Ethics Committee of the First
Affiliated Hospital, Guangxi Medical University.
Informed consent was obtained from all subjects.
Epidemiological survey
The survey was carried out using internationally stan-
dardized methods [26]. Information on demographics,
socioeconomic status, and lifestyle factors was collected
with standardized questionnaires. The alcohol informa-
tion included questions about the number of liangs
(about 50 g) of rice wine, corn wine, rum, beer, or
liquor consumed during the preceding 12 months. Alco-
hol consumption was categorized into groups of grams
of alcohol per day: < 25 and ≥ 25. Smoking status was
categorized into groups of cigarettes per day: < 20 and ≥
20. Sitting blood pressure was measured using a mer-
cury sphygmomanometer on 3 separated intervals after
the subjects had a 5-minute rest, and the average of the
three measurements was used for the level of blood
pressure. Body mass index (BMI) was calculated as




Venous blood samples were obtained from all subjects
after at least 12 hours of fasting. The levels of serum
TC, TG, HDL-C, and low-density lipoprotein cholesterol
(LDL-C) in samples were determined by enzymatic
methods with commercially available kits. Serum ApoAI
and ApoB levels were detected by the immunoturbidi-
metric immunoassay using a commercial kit [24,25].
DNA amplification and genotyping
Genomic DNA was isolated from peripheral blood leu-
kocytes using the phenol-chloroform method [27]. Gen-
otyping of the ACAT-1 rs1044925 SNP was performed
by polymerase chain reaction and restriction fragment
length polymorphism (PCR-RFLP) [22,27,28]. PCR
amplification was performed using 5’-TATAT-
TAAGGGGATCAGAAGT-3’ and 5’-CCACCTAAAAA-
CATACTACC-3’ (Sangon, Shanghai, People’s Republic
of China) as the forward and reverse primer pairs;
respectively. After Rsa I restriction enzyme digestion of
the amplified DNA, genotypes were identified by
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ethidium-bromide staining ultraviolet illumination. Gen-
otypes were scored by an experienced reader blinded to
epidemiological data and serum lipid levels. Six samples
(AA, AC and CC genotypes in two; respectively)
detected by the PCR-RFLP were also confirmed by
direct sequencing.
Statistical analyses
All statistical analyses were done with the statistical
software package SPSS 13.0 (SPSS Inc., Chicago, Illi-
nois). Quantitative variables were expressed as mean ±
standard deviation (serum TG levels were presented as
medians and interquartile ranges). Qualitative variables
were expressed as percentages. Allele frequency was
determined via direct counting, and the standard good-
ness-of-fit test was used to test the Hardy-Weinberg
equilibrium. Difference in genotype distribution between
the groups was obtained using the chi-square test. The
difference in general characteristics between normolipi-
demic and hyperlipidemic subjects was tested by the
Student’su n p a i r e dt-test. The association of genotypes
and serum lipid parameters was tested by analysis of
covariance (ANCOVA). Sex, age, BMI, blood pressure,
alcohol consumption, cigarette smoking were adjusted
for the statistical analysis. A P value of less than 0.05
was considered statistically significant.
Results
General characteristics and serum lipid levels
Table 1 gives the general characteristics and serum lipid
levels between the normolipidemic and hyperlipidemic
subjects. The levels of BMI, systolic blood pressure, dia-
stolic blood pressure, serum TC, TG, HDL-C, LDL-C,
ApoAI and ApoB were lower, and the ratio of ApoAI to
ApoB were higher in normolipidemic than in hyperlipi-
demic subjects (P < 0.05-0.001). The percentage of sub-
jects who consumed alcohol < 25 g/day was higher and
the percentage of subjects who consumed alcohol ≥ 25
g/day was lower in normolipidemia than in hyperlipide-
mia (P < 0.01). There was no significant difference in
the levels of pulse pressure, age structure, the percen-
tage of subjects who smoked cigarettes, or the ratio of
male to female between the two groups.
Genotypic and allelic frequencies
The frequency of ACAT-1 alleles and genotypes is
shown in Table 2. The frequency of A and C alleles
was 86.7% and 13.3% in normolipidemia, and 88.0%
and 12.0% in hyperlipidemia (P > 0.05); respectively.
The frequency of AA, AC and CC genotypes was
74.8%, 23.8% and 1.4% in normolipidemia, and 77.3%,
21.4% and 1.3% in hyperlipidemia (P >0 . 0 5 ) ;r e s p e c -
tively. There was also no significant difference in the
genotypic and allelic frequencies between males and
females in both groups.
Genotypes and serum lipid levels
A ss h o w ni nT a b l e3 ,t h el e v e l so fT C ,H D L - Ca n d
ApoAI in hyperlipidemia but not in normolipidemia
were different between the AA and AC/CC genotypes in
males but not in females (P < 0.05 for all). The subjects
with AC/CC genotype had higher serum TC, HDL-C
and ApoAI levels than the subjects with AA genotype.
There was no difference in serum lipid parameters
between the AA and AC/CC genotypes in normolipide-
mia (P > 0.05 for all). When hyperlipidemia was divided
into hypercholesterolemia and hypertriglyceridemia, we
found that the levels of HDL-C and ApoAI in hypercho-
lesterolemia but not in hypertriglyceridemia were differ-
ent between the AA and AC/CC genotypes in males but
not in females (Table 4), the subjects with AC/CC geno-
type had higher serum HDL-C and ApoAI levels than
the subjects with AA genotype. In addition, we also
found that the levels of TC in male hypercholesterole-
mia or hypertriglyceridemia were not different between
the AA and AC/CC genotypes. But the levels of TC in
female hypercholesterolemia but not in female hypertri-
glyceridemia were lower in AC/CC genotype than in AA
genotype (P < 0.05).
Discussion
In the present study, we showed that the levels of HDL-
C, LDL-C, ApoAI and ApoB were higher in subjects
with hyperlipidemia than in subjects with normolipide-
mia besides serum TC and TG levels, whereas the ratio
of ApoAI to ApoB was lower in subjects with hyperlipi-
demia than in subjects with normolipidemia. Although
t h ee v i d e n c es u g g e s t st h ei n v e r s er e l a t i o no fs e r u m
HDL-C and TG levels [29], the mechanism of this asso-
ciation is still unclear. In several our previous studies
[24,25], elevated serum HDL-C and TG levels was
found consistently in the hypertensives, drinkers and
obese subjects. It is well known that dyslipidemia is a
multifactorial origin, including hereditary and acquired
risk factors.
The genotypic and allelic frequencies of ACAT-1
rs1044925 SNP in diverse populations are inconsistent.
Zhao et al. [28] reported that there was not different in
the minor allele frequency between normal controls
(9.7%) and Alzheimer’s disease patients (9.3%). In
another recent study, Li et al. [22] also found no signifi-
cant difference in the C allele frequency between normal
controls (13.7%) and endogenous hypertriglyceridemia
patients (15.3%). However, the C allele frequency of
ACAT-1 rs1044925 SNP was very high in the popula-
tion of central and Southern Europe (35.4%) [30]. In the
current study, we showed that there were no significant
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ACAT-1 rs1044925 SNP between normolipidemia and
hyperlipidemia (13.3% vs. 12.0%, P > 0.05), or between
males and females in both groups. These results indicate
that the ACAT-1 rs1044925 SNP may have a racial/eth-
nic, or disease specificity.
In the present study, the associations of ACAT-1
rs1044925 SNP and serum lipid levels were determined
according to the subjects with or without hyperlipide-
mia. We found that the effect of ACAT-1 rs1044925
SNP on serum TC, HDL-C and ApoAI was more pro-
minent in subjects with hyperlipidemia than in subjects
Table 1 The general characteristics and serum lipid levels between the normolipidemic an hyperlipidemic subjects
Parameter Normolipidemia Hyperlipidemia t (c
2) P
Number 345 476 - -
Male/female 154/191 224/252 0.472 0.492
Age (years) 42.50 ± 14.91 43.82 ± 15.26 -1.240 0.215
Body mass index (kg/m
2) 22.30 ± 2.63 23.34 ± 3.36 -4.954 0.000
Systolic blood pressure (mmHg) 120.85 ± 15.84 124.74 ± 17.37 -3.331 0.001
Diastolic blood pressure (mmHg) 75.30 ± 9.99 78.98 ± 10.73 -5.045 0.000
Pulse pressure (mmHg) 45.57 ± 11.67 45.76 ± 11.81 -0.220 0.826
Cigarette smoking [n (%)]
Nonsmoker 242(70.1) 336(70.6)
< 20 cigarettes/day 37(10.7) 36(7.6) 2.968 0.227
≥20 cigarettes/day 66(19.1) 104(21.8)
Alcohol consumption [n (%)]
Nondrinker 206(59.7) 290(60.9)
< 25 g/day 119(34.5) 130(27.3) 11.146 0.004
≥ 25 g/day 20(5.8) 56(11.8)
Total cholesterol (mmol/L) 4.31 ± 0.59 5.60 ± 0.96 -23.796 0.000
Triglyceride (mmol/L) 0.89(0.42) 1.59(1.11) -14.552 0.000
HDL-C (mmol/L) 1.89 ± 0.41 1.97 ± 0.58 -2.035 0.042
LDL-C (mmol/L) 2.37 ± 0.49 3.15 ± 0.87 -16.334 0.000
Apolipoprotein (Apo) AI (g/L) 1.41 ± 0.22 1.50 ± 0.31 -4.857 0.000
ApoB (g/L) 0.82 ± 0.15 1.05 ± 0.23 -16.887 0.000
ApoAI/ApoB 1.79 ± 0.56 1.51 ± 0.58 6.762 0.000
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. The value of triglyceride was presented as median (interquartile range),
the difference between the two groups was determined by the Wilcoxon-Mann-Whitney test.
Table 2 The genotype and allele frequencies of ACAT1 rs1044925 SNP between the normolipidemic and
hyperlipidemic subjects [n (%)]
Group n Genotype Allele
AA AC CC A C
Normolipidemia 345 258 (74.8) 82 (23.8) 5 (1.4) 598 (86.7) 92 (13.3)
Hyperlipidemia 476 368 (77.3) 102 (21.4) 6 (1.3) 838 (88.0) 114 (12.0)
c
2 - 0.709 0.673
P - 0.701 0.412
Normolipidemia
Male 154 111 (72.1) 42 (27.3) 1 (0.6) 264 (85.7) 44 (14.3)
Female 191 147 (77.0) 40 (20.9) 4 (2.1) 334 (87.4) 48 (12.6)
c
2 - 2.938 0.437
P - 0.230 0.509
Hyperlipidemia
Male 224 168 (75.0) 52 (23.2) 4 (1.8) 388 (86.6) 60 (13.4)
Female 252 200 (79.4) 50 (19.8) 2 (0.8) 450 (89.3) 54 (10.7)
c
2 - 1.848 1.614
P - 0.397 0.204
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AA 258 4.30 ± 0.61 0.89(0.42) 1.90 ± 0.41 2.37 ± 0.49 1.41 ± 0.22 0.82 ± 0.15 1.79 ± 0.59
AC/CC 87 4.34 ± 0.50 0.92(0.48) 1.87 ± 0.42 2.37 ± 0.50 1.41 ± 0.22 0.82 ± 0.14 1.77 ± 0.49
F - 0.201 -1.034 0.323 0.009 0.009 0.000 0.083
P - 0.654 0.301 0.570 0.926 0.927 0.994 0.773
Male
AA 111 4.25 ± 0.73 0.90(0.42) 1.86 ± 0.42 2.37 ± 0.54 1.38 ± 0.22 0.83 ± 0.17 1.76 ± 0.68
AC/CC 43 4.27 ± 0.48 0.89(0.37) 1.80 ± 0.47 2.33 ± 0.48 1.35 ± 0.21 0.83 ± 0.13 1.67 ± 0.41
F - 0.029 -0.173 0.608 0.171 0.579 0.000 0.662
P - 0.866 0.862 0.437 0.680 0.448 0.988 0.417
Female
AA 147 4.34 ± 0.51 0.88(0.41) 1.94 ± 0.41 2.36 ± 0.46 1.43 ± 0.21 0.82 ± 0.14 1.82 ± 0.51
AC/CC 44 4.43 ± 0.52 0.96(0.50) 1.94 ± 0.35 2.45 ± 0.51 1.46 ± 0.22 0.82 ± 0.15 1.86 ± 0.55
F - 1.062 -1.293 0.000 1.067 0.667 0.034 0.234
P - 0.304 0.196 0.996 0.303 0.415 0.854 0.629
Hyperlipidemia
AA 368 5.57 ± 0.96 1.60(1.12) 1.95 ± 0.57 3.15 ± 0.87 1.49 ± 0.30 1.04 ± 0.22 1.51 ± 0.60
AC/CC 108 5.72 ± 0.96 1.53(1.08) 2.04 ± 0.64 3.15 ± 0.84 1.53 ± 0.34 1.06 ± 0.24 1.51 ± 0.49
F - 2.314 -0.630 2.401 0.006 1.465 0.389 0.000
P - 0.129 0.529 0.122 0.940 0.227 0.533 0.995
Male
AA 168 5.48 ± 0.92 1.78(1.51) 1.87 ± 0.53 3.06 ± 0.89 1.48 ± 0.30 1.02 ± 0.24 1.59 ± 0.79
AC/CC 56 5.84 ± 1.03 1.75(2.04) 2.10 ± 0.74 3.13 ± 0.99 1.58 ± 0.37 1.03 ± 0.27 1.63 ± 0.59
F - 5.911 1.005 9.060 0.309 5.382 0.192 0.135
P - 0.016 0.315 0.003 0.579 0.021 0.662 0.714
Female
AA 200 5.63 ± 0.98 1.50(1.03) 2.01 ± 0.59 3.23 ± 0.85 1.50 ± 0.30 1.06 ± 0.20 1.45 ± 0.37
AC/CC 52 5.61 ± 0.87 1.48(0.99) 1.96 ± 0.51 3.17 ± 0.64 1.46 ± 0.29 1.09 ± 0.21 1.38 ± 0.31
F - 0.028 -0.081 0.312 0.286 0.803 0.521 1.912
P - 0.868 0.935 0.577 0.593 0.371 0.471 0.168
TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; ApoAI, apolipoprotein AI; ApoB,
apolipoprotein B
















AA 76 5.79 ± 0.53 2.20 ± 0.53 1.55 ± 0.27 AA 92 5.25 ± 1.10 1.62 ± 0.41 1.41 ± 0.32
AC/CC 26 5.97 ± 0.70 2.49 ± 0.66 1.76 ± 0.37 AC/CC 30 5.66 ± 1.23 1.70 ± 0.41 1.43 ± 0.25
F - 1.785 5.742 9.200 F - 2.905 0.998 0.053
P - 0.185 0.019 0.003 P - 0.091 0.320 0.819
Female Female
AA 118 5.92 ± 0.84 2.27 ± 0.51 1.60 ± 0.31 AA 82 5.23 ± 1.04 1.64 ± 0.49 1.37 ± 0.24
AC/CC 36 5.62 ± 0.39 2.14 ± 0.38 1.52 ± 0.25 AC/CC 16 5.55 ± 1.48 1.45 ± 0.47 1.31 ± 0.29
F - 4.406 1.890 1.762 F - 1.435 2.273 0.934
P - 0.046 0.171 0.186 P - 0.234 0.135 0.336
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association of ACAT-1 rs1044925 SNP and serum
HDL-C and ApoAI levels in subjects with hypercholes-
terolemia but not in subjects with hypertriglyceridemia.
In a previous study, Ohta et al. [23] have found that the
-77G > A variant affected serum HDL-C and ApoAI
concentriations in hyperlipidemic subjects. The concen-
tration of plasma HDL-C and ApoAI were significantly
higher in A allele carriers than in A allele noncarriers.
This is consistent with our results in the ACAT-1
rs1044925 SNP. In the current study, however, we
found that the associations of ACAT-1 rs1044925 SNP
and serum HDL-C and ApoAI levels were only in the
hypercholesterolemic subjects. To our knowledge, these
findings have not been previously explored. It is
unknown whether the ACAT-1 variants influence the
ACAT1 activity. Ohta et al. [23] have shown a relation
between the -77G > A mutation and the plasma HDL
concentration in hyperlipidemic subjects. It is likely that
ACAT-1 gene with the mutation may not provide
enough ACAT-1 protein for efficient catalysis of
increased intracellular free cholesterol in the lipid-loa-
den status. The increased free cholesterol will increase
the efflux of cholesterol as well as increase the concen-
tration of serum HDL-C and ApoAI. In another study
of the association of ACAT-1 rs1044925 SNP and
plasma lipid levels, however, Li et al. [22] found that
serum HDL-C levels in patients with endogenous hyper-
triglyceridemia in China were lower in the C allele car-
riers than in C allele noncarriers. These findings were
opposite with our results in the male hypercholesterole-
mic but not in hypertriglyceridemic subjects.
In the present study, we showed that the C variant of
ACAT-1 rs1044925 SNP could increase serum HDL-C
and ApoAI levels in the male subjects with hypercholes-
terolemia, which may play a protective factor for athero-
sclerosis. In lipid-loaden macrophages, however, it was
confirmed that ACAT-1 depletion in macrophages is
proatherogenic [15,16]. To explain these conflicts, the
possible reasons might as follows: Firstly, in the ACAT-
1 deletion modol, the ABCA1-mediated cholesterol
efflux to protect macrophages from free cholesterol toxi-
city may be not sufficient in the status of completely
lack of ACAT-1 [23]. While in our study, the ACAT-1
rs1044925 SNP did not affect the ACAT-1 activity
greatly. The pathways of the ABCA1-mediated choles-
terol efflux may be sufficient in the physiological status.
If there are some defects in the pathways of the
ABCA1-mediated cholesterol efflux, the efflux of the
cholesterol will decrease and the free cholesterol will
increase in the cell. Thus, the rs1044925 C variant with
the gene variants in pathways of the cholesterol efflux
could be at higher risk for atherosclerosis. Secondly,
ACAT-1 is ubiquitously expressed in various tissues and
cells including adrenal glands, kidney and macrophages.
N o to n l yf r o mm a c r o p h a g e s ,t h ec i r c u l a t i n gH D L - C
levels were regulated by the cholesterol efflux from
these cells that the ACAT-1 expressed in, therefore, the
circulating HDL-C levels might reflect the cholesterol
efflux from the others cell and tissues. Furthermore,
although epidemiological studies demonstrated an
inverse relationship between HDL-C levels and coronary
heart disease, the serum HDL-C levels in part but do
not always reflect cholesterol efflux capacity, a key
metric of HDL function [31]. In the present study, we
did not determine the association of ACAT-1 rs1044925
SNP and the level of cholesterol efflux, HDL particle
sizes, as well as the extent of atherosclerosis. The only
result directly present in our study was that the ACAT-
1 rs1044925 SNP influenced the HDL-C and ApoAI
levels in the male with hyperlipidemia, which suggests
that the ACAT-1 rs1044925 SNP might influence the
cellular cholesterol efflux in the male hyperlipidemic
subjects.
In addition, we also found that serum TC levels were
higher in AC/CC than in AA genotypes in the male
hyperlipidemic subjects, but the levels of TC in male
hypercholesterolemia or hypertriglyceridemia were not
different between the AA and AC/CC genotypes. The
levels of TC in female hypercholesterolemia but not in
female hypertriglyceridemia were lower in AC/CC gen-
otype than in AA genotype. The reason for this discre-
pancy is unclear. In ACAT-1 deficiency macrophages,
cholesterol synthesis was increased by 134% in ACAT1
(-/-) macrophages compared to wildtype macrophages,
which suggests that ACAT-1 affects the regulation of
cholesterol metabolism in macrophages [32]. There-
fore, the ACAT-1 rs1044925C variant had a higher TC
levels may attribute to the C variant of the rs1044925
SNP could not produce enough ACAT-1 protein and
induce an increased cholesterol synthesis in the
macrophages.
Conclusion
The present study shows that serum HDL-C and ApoAI
levels in the male subjects with hypercholesterolemia
but not in those with hypertriglyceridemia were signifi-
cantly different between the AA and AC/CC genotypes.
These results suggest that there is a sex (male)-specific
association of ACAT-1 rs1044925 SNP and serum
HDL-C and ApoAI levels in the hypercholesterolemic
subjects. The ACAT-1 rs1044925 SNP might influence
the cellular cholesterol efflux, and indirectly modulate
serum HDL-C concentrations.
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